Prucalopride is a benzofurane dihydro benzofuran carboxamide compound that activates 5-HT4 receptors preferentially and consequently has enterokinetic characteristics. Prucalopride's strong selectivity enabled further development because it prevented cardiac side effects caused by non-target effects of previous medications. Shire Development LLC developed Prucalopride, which was licensed for use in Europe in 2009, Canada on November 7, 2011, and the United States on December 17, 2018. Prucalopride stimulated extension of existing in the small bowel and inhibited contractility in the small bowel in a dose-dependent manner. Prucalopride has also been proven to induce and amplify gigantic migratory contractions, which are the high-amplitude contractions that trigger the urge to defecate. As a result, prucalopride speeds up not just colonic passage but also gastrointestinal motility and small intestinal transit.

Prucalopride is a specific 5-HT4 receptor activator that does not bind with the hERG channel or 5-HT1 receptors, lowering the cardiovascular risk associated with other comparable medications. Smooth muscle, enterochromaffin cells, and myenteric plexus contain 5-HT4 receptors, which are present throughout the intestinal system. Acetylcholine, the principal excitatory transmitter in the GI tract, is released when it is activated. As a result, prucalopride increases motility by interacting specifically with 5-HT4 transmitters in the GI tract, causing acetylcholine production and additional tension of the colon's muscular layer, as well as relaxation of the circumferential muscle layer, resulting in luminal contents propelling.

Based on the drugstore you visit, Prucalopride oral tablet 1 mg costs roughly $493 for a batch of 30 tablets. This medicine is available for sale at a variety of prices from a variety of manufacturers and drugstores. The wholesale prices are solely valid for cash-paying customers and do not apply to insurance policies. Patient assistance programs, which provide free or subsidized drugs to low-income, unemployed, or sick individuals who meet specified criteria, are often supported by pharmaceutical companies.

Being a global B2B pharmaceutical online marketplace, Pipelinepharma is structured to simplify pharmaceutical deals by providing you with an intuitive interface that is easy to engage with. The selection of Prucalopride Succinate offerings can be narrowed down with the use of filters and easily weighed against one another according to medication prices and commercial terms. The advanced filters help you filter out the countries for this substance manufacturer and Prucalopride Succinate suppliers that you are looking for. These also enable you to check the dossier status of this medicine, and the GMP approvals of the different variants of Prucalopride Succinate. Also, each manufacturer or supplier product description contains essential information about this substance including clinical data, stability zones, countries where Prucalopride Succinate is already registered in. Manufacturers also have special, and delivery terms.

If you are a pharmaceutical licensing company or a distributor you can enter into deals or negotiations over these medicine offers with manufacturing companies after completing the free registration process and joining our online marketplace. This helps to ensure that you conclude the pharmaceutical deal at a reasonable cost and achieve the best cost/benefit ratio for your company while bypassing lengthy sourcing, negotiation, and order process. Once you have finalized a deal, you can look forward to a long-lasting business relationship with the Prucalopride Succinate suppliers. This way, the marketplace allows you as a distributor to skip the process of making a list of product manufacturers every time you are looking for in-licensing or distribution deals.

To keep up to the quality standards other than Good Manufacturing Practice approvals that this medicine manufacturers list has, we qualify their companies before they are boarded on the platform. This allows us to screen Prucalopride Succinate manufacturers for the quality of the pharmaceutical products’ dossiers and protect against the risk of possible malpractices.